Member Info for Laura2022

That's crazy Geordie

As for PIP

.a £700k market cap is too low even with QM , particularly as some PIP divisionsmay benefit from Labour new economic infrastructure plans

CPX has gone 400% since their placing and valued at nearly £10mln!! With very similar revenue figures to PYC (clearly a very different sector )

Be great to see the same here

A quiclnlook at their posts since joining LSE in May says alot

Related party transactions

As announced on 29 November 2022, my letter of financial support dated 6 September 2021 was renewed on 11 October 2022 to provide the group with financial support until 31 December 2024.

Scmd

I have purchased a first small amount and the price looks rock bottom on the technical indicators (only just learning !!)

Now that PYC is funded it makes PYC a strong buy for market cap of £900k but revenues booked of £950k last month and cash now after placing of Bout £600k ( Inl bought more yesterday)

Thanks, I've not bought any as yet but on my watch out

will not impact PipeHawk's broader group of companies and the Board believes that the remainder of the Group will be able to continue to trade as a going concern. Trading within the Group's other key subsidiaries, being Thomson Engineering Design Ltd, Adien Ltd and Utsi Electronics Ltd, currently remains in line with management's expectations.

Thankyou Newbie

A large holder only just added a month or so ago at over 7-8p

They have said the other divisions are still trading, and the CEO has funded the company via director loans...he will want a return ?

£700k market value seems very unfair when the other divisions contribute about £2mln in sales ?

Looks tempting

Any views ?

Hi clarets

Be useful to also know if the main placing was also scaled back, of so it might mean we can quickly get back where we were above 1.2/11.3

Let's now await further contracts and updates

From Friday 5th July

WRAP Retail Offer, which closed at 4:30 p.m. yesterday and which was oversubscribed, has raised gross proceeds of £25,000 through the issue of a total of 4,166,667 new Ordinary Shares to existing retail shareholders in the United Kingdom.

Hi jacklin

Because it was OVERSUBSCRIBED which means more people wanted shares than were available ( a good sign!!)

I had the same ...I subscribed for £3000 but only got £630..so I bought more today at market prices

Purchased some more and also took some in the WRAP offer to bring my holding to 2,150,090 shares

Rachel Reeves will promise to make kickstarting economic growth a "national mission", in her first speech as chancellor.

Speaking to business leaders at the Treasury later, Ms Reeves will set out Labour's plan for the economy and say the era of "chaos and irresponsibility is over".

She is also expected to announce she will bring back compulsory house building targets, as part of an overhaul of Britain's planning rules.

And she will say that with political turmoil in the France and the US, Britain is now back as one of the most stable places for international investment.

Former Bank of England economist Ms Reeves was appointed chancellor on Friday, after Labour's landslide election win.

She and her team worked through the weekend on this speech to business leaders and investors who have stalled investment in Britain in recent years amid the political chaos of the post-Brexit years and the Liz Truss mini-budget.

Ms Reeves is expected to announce some immediate loosening of planning red tape that has held back construction, infrastructure, and the energy grid.

It will be done in the hope that investors will unleash tens of billions of pounds of investment in green industry and housebuilding.

Mandatory housebuilding targets are also expected to return.

The new person certainly looks like he'll be heading the biostatistics division based on his background

He has a strong background in statistical methodologies such as adaptive Bayesian design, Bayesian Dynamic Borrowing (BDB), and implementing estimands and sensitivity analysis, mixed models, survival analysis, missing data imputation, meta-analysis, modeling structured data, predictive modeling using classical or Bayesian approaches, and Machine Learning/AI techniques (such as clustering, classification, and data reduction).

Many of Dr Ghebre’s publications can be found here.

Morning both

I would imagine all this will be covered in the upcoming presentation but to have that much visibility is reassuring , it may also be the pipleine of biostatistics work for which the recent appointment ( 2 weeks ago ? ) on the website was done

They did say the biostatistics division would add "significant" revenues fY 2024/25

I

Deos anyone know what the revenues come from going forward 2 years ?

Is it from existing clients who have drug trials in those years ?

From.last weels RNS

Increased investment in business development and marketing, culminating in a peak pipeline value at over £1.5m (unweighted) as announced on 7 March 2024, a record year (FY2023/24) for total value of new contracts won, and over £500k of revenue already contracted for next year (FYE 2025), with additional revenue contracted into the following two years (FYE 2026 and 2027).

Yes lone

It is certainly good that they are investing £1mln

I won't post again but was getting tired of raw fish talking nonsense on other shares while exuberant ramping on ones he was /is in while admitting he has lot sof investments 90% down or de listed

Maybe he should show a little humility

Gluck SIS

It also depends where some of the main placing has gone

As you and Ant have said we may know more once the shares are admitted

Great track record t0 be giving advice